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Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by a largely irreversible airflow obstruction
and a persistent, excessive inflammatory response. Alveolar macrophages (AMs) are increased in the lungs of COPD
patients, and act as orchestrators of the inflammatory response, releasing a range of mediators to coordinate
recruitment and activation of leukocytes. Attempts to treat the inflammatory component of COPD with
anti-inflammatory drugs such as steroids has met with limited success. In this study, we compared the ability of the
phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein
kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs
isolated from COPD lung transplant tissue. All studies were carried out with appropriate ethical approval and
written, informed consent was obtained from each subject. Cilomilast had little effect on cytokine release from AMs.
There was considerable variability in the responsiveness of AMs to Budesonide, with a subset of AMs responding
poorly to Budesonide. BIRB-796 inhibited TNFα release from all AM donors, including those that responded poorly
to steroids. Treatment with BIRB-796 and Budesonide together gave an additive decrease in TNFa release. These
results suggest that a p38 inhibitor may provide advantages over existing anti-inflammatory treatments for COPD,
either as an add-on to existing therapy, or to treat patients who respond poorly to steroids.
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COPD is an increasingly prevalent disease, affecting up
to 10% of adults aged over 40 years [1]. Current therap-
ies include long acting β2-receptor agonists (LABAs)
and muscarinic receptor antagonists, which increase
lung function by relaxing airway smooth muscle. Cor-
ticosteroids are also used, and have been shown to
decrease exacerbations as well as improving other clin-
ical parameters such as FEV1[2]. However, the use of
inhaled steroids in COPD is somewhat controversial due
to inconsistent clinical effects and reports that these
agents have limited effects on lung inflammation in
COPD patients. For example, a meta-analysis of the* Correspondence: Marianne.ratcliffe@astrazeneca.com
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distribution, and reproduction in any mediumeffects of inhaled corticosteroids on inflammatory cells in
the sputum of stable COPD patients showed evidence of
reductions in neutrophils and lymphocytes but no effect on
macrophages [3]. A similar analysis conducted recently on
bronchial biopsies and bronchoalveolar lavage (BAL) fluid
from stable patients showed reductions in neutrophils and
lymphocytes in BAL but an increase in macrophages. The
biopsy analysis indicated no effect on neutrophil and
macrophage counts but a reduction in CD4+ and CD8+
lymphocytes [4]. In accordance with these results, macro-
phages from COPD patients have been reported to be in-
sensitive to steroids [5,6]. Various mechanisms for this
steroid insensitivity have been proposed, including up-
regulation of NF-kB signaling and increased oxidative stress
[7]. If specific mechanisms are indeed responsible for the
poor efficacy of steroids in COPD, then alternative anti-
inflammatory approaches may be more successful. OneCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.




























Figure 1 TNFα (A) and IL-6 (B) release in response to LPS
stimulation in COPD lung macrophages as measured by ELISA
(n =11). Data is expressed as mean ± s.e.
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PDEIV, by drugs such as Roflumilast and Cilomilast. The
former drug has recently been approved as an add-on the-
rapy for the maintenance treatment of severe COPD in the
European Union and as a treatment to reduce the risk of
exacerbations in the United States. These cAMP elevating
agents have been shown to reduce recruitment of macro-
phages and CD8+ T-cells in COPD biopsies [8] and im-
prove FEV1, alone or in combination with a bronchodilator
therapy [9,10]. p38 MAP kinase is involved in transducing a
number of inflammatory stimuli [11] and inhibitors of this
enzyme have broad anti-inflammatory potential. Indeed,
p38 inhibitors have shown evidence of anti-inflammatory
effects and improvements in clinical parameters in COPD
patients [12,13]. Such agents have also been shown to in-
hibit cytokine release from human AMs derived from
patients with COPD [14,15], but the effectiveness of p38
inhibitors, steroids and PDEIV inhibitors has not been dir-
ectly compared in the same donors.
In the present study we compared the ability of Cilomi-
last, Budesonide and BIRB-796 to inhibit cytokine release
from AMs isolated from patients undergoing COPD lung
transplant surgery for severe end stage disease (GOLD
IV). This allowed us to directly compare the effectiveness
of different mechanisms in modulating cytokine release,
and assess donor to donor variability in response.
Results
Characterisation of LPS response
A concentration-effect curve to LPS was generated in
AMs from eleven COPD transplant donors, measuring
both IL-6 and TNFα release. All donors responded to
LPS, with potency values of p[A]50 = 8.2 (6 ng/ml) for
TNFα and 8.3 (4 ng/ml) for IL-6. Meaned maximal res-
ponse was 6.3 ± 1.6 ng/ml for TNFα and 34.1 ± 7.2 ng/ml
for IL-6 (Figure 1). These cytokine levels were similar or
greater to that seen in COPD macrophages used in simi-
lar published studies [14,15]. The concentration of LPS
(100 ng/ml) subsequently used for testing the effects
of the anti-inflammatory agents corresponded to a maxi-
mum response for both cytokine readouts.
Response of COPD AMs to Cilomilast
The ability of Cilomilast, a PDEIV inhibitor, to inhibit
LPS-induced cytokine release was tested. Cilomilast did
not inhibit IL-6 release at any of the concentrations used
(Figure 2B), and only inhibited TNFα release at concen-
trations greater than 300 nM (Figure 2A) reaching max-
imum levels of inhibition of 34.2 ± 6.0 at 10 μM.
Anti-inflammatory effects of Budesonide in COPD AMs
The ability of the steroid Budesonide to inhibit TNFα or
IL-6 release from COPD AMs was tested. Budesonide
inhibited TNFα release by a maximum of 42.9% ± 8.0%,with a pIC50 of 8.9 (1.3 nM). A similar potency was seen
against IL-6 (pIC50 = 9.0), although the maximum effect
was lower than for TNFα (30.8% ± 9.4%) (Figure 3).
Response of COPD AMs to BIRB-796
The ability of BIRB-796, a p38 inhibitor, to inhibit
macrophage cytokine release was also tested. BIRB-796
inhibited TNFα with a pIC50 = 8.3 (5 nM) and a max-
imum inhibition of 63.9% ± 4.6% (Figure 4A). Effects on
IL-6 release were less marked and more variable, result-
ing in a relatively poor fit to equation 2. The maximum
inhibition achieved was 38.4% ± 8.6%, and a pIC50 esti-
mated as 8.2 (6.3 nM).











































Figure 2 Effect of Cilomilast on LPS-induced TNFα (A) or IL-6
(B) release from COPD lung macrophages (n =11). Data is
expressed as mean ± s.e.
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Figure 3 Effect of Budesonide on LPS-induced TNFα (A) or IL-6
(B) release from COPD lung macrophages (n = 11). Data is
expressed as mean ± s.e. and the lines drawn through the points
are the result of fitting using equation 2.
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Although the AMs from the majority of COPD donors
responded to Budesonide, we observed considerable
variability in the potency and maximum effect of Bude-
sonide between different donors. For inhibition of TNFα,
the average standard deviation across the concentration
range in COPD donors was 21.3% for Budesonide. In
comparison, the p38 response was much less variable,
with an average standard deviation of 12.4%. Of note,
three of the COPD donors were either unresponsive, or
poorly responsive to steroid as defined by showing less
than 30% inhibition of LPS-induced TNFα release at the
maximal concentration of Budesonide used. The data for
these three donors were separated from the remaining
donors and re-plotted (Figure 5A). The inhibitory effectof BIRB-796 in these three steroid refractory cells was
similar to the steroid responsive AMs (Figure 5B). Thus
the ability of BIRB-796 to inhibit TNFα release was main-
tained in cells with poor steroid sensitivity. We confirmed
that the potency of the LPS response in the steroid re-
sistant donors was not significantly different from that of
the steroid sensitive donors, ruling out the possibility that
shift in the potency of LPS could have explained the dif-
ferential response to steroid (Figure 5C). The average le-
vels of TNFα release from the steroid responsive donors
appeared higher than in the non-responsive, but since the
groups are small the significance of this is unclear. The




































Figure 4 Effect of BIRB-796 on LPS-induced TNFα (A) or IL-6 (B)
release from COPD (lung macrophages (n = 11). Data is
expressed as mean ± s.e. and the lines drawn through the points
are the result of fitting using equation 2.
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(0.6-7.6 ng/ml) lay within the range seen in the steroid res-
ponsive group (0.3-15.4 ng/ml).
Combination of BIRB-796 and budesonide
Combination therapy is an increasing trend within the
respiratory area, in an attempt to increase the thera-
peutic efficacy of medications. The combined effect of
Budesonide and BIRB-796 was assessed in COPD AMs.
Using a maximally effective concentration of Budesonide
(100 nM), an additive effect of BIRB-796 on the release
of TNF in response to LPS was observed (Figure 6).Discussion
We have investigated the pharmacological profile of
three different anti-inflammatory agents in COPD lung
macrophages. We used LPS as a stimulus, given the
strong links between bacterial colonization and exacer-
bations of COPD [16]. TNF and IL-6 are both pleio-
tropic, pro-inflammatory cytokines which are elevated in
COPD patients [17,18]. Furthermore, genetic poly-
morphisms in both these cytokines have been linked to
development of COPD [19,20]. The response to the
PDEIV inhibitor, Cilomilast, was poor, consistent with
published data showing limited effects of PDEIV inhibi-
tors in inhibiting cytokine production from human
macrophages [21,22]. Such data suggests that suppres-
sion of macrophage function is not a key contributor to
the observed clinical efficacy of PDEIV inhibitors in
COPD, which may instead lie with anti-inflammatory
effects on other cells such as neutrophils or epithelial
cells. Alternatively, the modest potency of cilomilast
may have limited the effects of this agent and therefore
it would be interesting to evaluate the properties of
other PDEIV inhibitors. The steroid Budesonide and the
p38 inhibitor BIRB-796 were effective anti-inflammatory
agents in alveolar macrophages although their effective-
ness was dependent on the particular cytokine readout.
TNFα release was significantly inhibited by both com-
pounds, but IL-6 was more resistant to inhibition. Other
studies have also demonstrated efficacy of steroids in re-
ducing cytokine release from COPD macrophages, with
the magnitude of the effect varying between readouts
[15,23] . In our study, AMs exhibited a broad spectrum
of sensitivities to Budesonide ranging from one donor
which failed to show any inhibition of cytokine release,
to donors in which the steroid gave over 75% inhibition
of TNFα release. This data suggests that cellular steroid
insensitivity may not be characteristic of COPD. Rather,
there appears to be a significant proportion of indivi-
duals whose show a poor cellular response to steroid.
Increasingly, physicians and payers are looking towards
personalized healthcare approaches, so that individuals
likely to respond or fail to respond to treatment can be
identified. Steroid treatment is linked to a range of ser-
ious side effects, and if those patients who are steroid
insensitive could be identified, an alternative treatment
option could be selected, thus avoiding unnecessary
exposure to steroid.
Of particular interest is our observation that BIRB-796
inhibited TNFα release from AMs equally well in COPD
donors that were good or poor responders to Budeso-
nide. This data indicates that p38 inhibitors might be ef-
fective in patients which respond poorly to steroids. p38
MAPK pathways have been shown to be active in COPD
[24] and a p38 inhibitor has been shown to down-
regulate a different panel of mediators to steroids, which




































































































































Figure 5 The effects of Budesonide (A) and BIRB-796 (B) in COPD AMs separated into donors resistant (< 30% inhibition of LPS-induced
TNFα release, n = 3), closed circles) or sensitive (> 30% inhibition, n = 8, open circles) to steroid. (C) LPS concentration-effection response
curve in steroid resistant (closed circles) or steroid sensitive (open circles) COPD donors. Data is expressed as mean ± s.e. and the lines drawn
through the points are the result of fitting using equations 1 (LPS data) and 2 (Budesonide and BIRB-796 data). Absolute cytokine release levels for
steroid responsive (D) and steroid non-responsive (E) groups in response to LPS alone and in the presence of 100 nM Budesonide or BIRB-796.
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Although a number of oral p38 MAPK inhibitors have
ceased development due to unwanted side-effects,
inhaled p38 inhibitors may have an acceptable thera-
peutic window and thus represent useful new anti-
inflammatory agents. Indeed, PF-03715455 is being
developed as an inhaled agent for the treatment of
COPD [25]. Such agents could be considered as steroid
replacements, or as a second-line treatment option in
patients with a poor response to steroid. Recent studies
have demonstrated additive effects of steroids and p38
inhibitors in reducing cytokine release from bronchoal-
veolar lavage (BAL) macrophages and PBMCs from asth-
matics [26] and COPD patients [27]. Our data confirms
and extends these results, demonstrating additive effects
of BIRB-796 and Budesonide in macrophages from a dif-
ferent compartment (lung tissue versus BAL) and to se-
vere (GOLD stage IV) COPD patients, as compared to
mild/moderate disease. Thus, our data adds to a growing
body of evidence suggesting that a combination of steroidplus p38 inhibitor, on the background of standard bron-
chodilator therapy, could deliver increased clinical efficacy
in severe COPD patients.
Conclusions
In a subset of subjects with GOLD IV stage COPD, ster-
oids are ineffective in reducing cytokine release from tis-
sue macrophages, yet the inhibitory response to the p38
MAPK inhibitor BIRB-796 is maintained in these cells.
Use of inhaled p38 MAPK inhibitors may therefore pro-
vide a more effective therapy than steroids in some
COPD patients. In addition, combination of steroid with
a p38 inhibitor provides additive anti-inflammatory ef-
fects in COPD lung tissue macrophages.
Methods
Reagents
LPS (E. coli 026:B6), Budesonide and Foetal Calf Serum
(FCS) were from Sigma-Aldrich, Poole, Dorset UK. Cilo-






























Figure 6 Combined effect of 100 nM Budesonide in the
presence of increasing concentration of BIRB-796 on LPS
induced TNFa release from COPD lung macrophages (n=5). A
two tailed T-test was performed to assess statistical significance.
* p values <0.05, ** p value <0.01.
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RPMI, DMEM, Iscoves modified Dulbecco’s medium con-
taining GlutaMAX™ (IMDM), L-glutamine and Penicillin/
Streptomycin were from Invitrogen Ltd, Paisley UK. Com-
pounds were made up in Dimethyl Sulfoxide (DMSO) at
1000x final concentration, such that the final concentra-
tion of DMSO was 0.1%.Subjects
All studies were approved by the Northumberland Local
Research Ethics Committee (REC reference 06/Q0902/
57). Written, informed consent was obtained from each
subject. The demographic and lung function data for the
COPD transplant patients are summarised in Table 1.
All patients had severe end stage disease and a diagnosis
of emphysema.Cytokine release assays
Human AMs were obtained from COPD patients under-
going lung transplant. Macrophages were flushed from the
tissue with phosphate buffered saline (PBS), then plated at
100,000 cells/well in 96 well plates in serum free RPMI for
1 hour. Contaminating cells were removed by stringentTable 1 Subject information. Data is average ± s.e
Sex (M/F) Age (years) FEV1 (l) FEV1/FVC (%)
COPD transplant
patients (n = 11)
6/5 52.9 ± 2.4 0.6 ± 0.1 28.3 ± 6.9washing in RPMI, and AMs rested in assay media for 1
hour prior to cytokine release experiments. The purity of
macrophages obtained by this process was confirmed as
>90% by Wright-Giemsa/May-Grünwald staining.
Cytokine release experiments were performed in
IMDM containing 0.5% FCS. Compounds were added
for 30 minutes, prior to addition of LPS (100 ng/ml final
concentration) and cells incubated for 20 hours. Super-
natants were harvested and cytokines measured using
optEIA ELISA kits (BD Biosciences, Erembodegen, Bel-
gium) according to manufacturer’s instructions. The
compounds had no effect on cell viability at the concen-
trations used as assessed by cellular morphology and/or
Wst-1 viability assays.
Data analysis
To estimate the potency of LPS, concentration-effect
curve data were fitted to the following form of the Hill
equation:
Ε ¼ α A½ 
nH
A½ nH þ A½ nH50
ð1Þ
in which α, [A]50 and nH are the upper asymptote (max-
imum effect), location (potency) and slope parameters,
respectively. [A]50 values were assumed to be log-
normally distributed and quoted as p[A]50 (−log[A]50)
values.
Similarly, potencies of Budesonide and BIRB-796 were
estimated by fitting inhibitory concentration-effect curve
data to a modified version of equation (1):
Ε ¼ α I½ 
nH
I½ nH þ IC½ nH50
ð2Þ
in which α, [IC]50 and nH are the upper asymptote (max-
imum effect), location (potency) and slope parameters,
respectively. [IC]50 values were assumed to be log-
normally distributed and quoted as p[IC]50 (−log[IC]50)
values. In all cases the individual concentration-effect
curve data was averaged and this mean data fitted to
equations 1 and 2. Maximum effects quoted in the
results sections are the measured values rather than the
values obtained from the fitting procedures. Percentage
inhibition was calculated by the equation: ((LPS in pres-
ence of compound – basal) ÷ (LPS in presence of vehicle
– basal)) × 100. All curve fitting was done using Graph-
Pad Prism software, using a non-linear regression curve
fit with least squares fit. Results are expressed and plot-
ted as mean ± s.e. Where appropriate, a two tailed
T-test was performed to assess statistical significance.
p values of <0.05 were considered significant.
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